Biological testing facility - "contraceptive drug and intravaginal contraceptive device evaluation"
Ended Awarded Last action
- Contract number
- 75N94020F00003
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $696,936
Award facts
- Contract value 100% obligated
- $696,935.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$3,101 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $700,037 |
About this award
Sri International, a prominent nonprofit research and development organization headquartered in Menlo Park, California, was awarded a delivery order on September 22, 2020, under the Biological Testing Facility Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle. The award, valued at approximately $697K, supports contraceptive drug and intravaginal contraceptive device evaluation activities for the National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health. The contract utilizes a cost-no-fee pricing structure and is classified as non-severable work, with performance conducted at Sri International's Menlo Park facility and a completion date of March 21, 2022. No small business set-aside was applied to this award.
This delivery order represents work under NICHD's research and development biological testing facility portfolio, which supports critical evaluation and safety assessment of contraceptive technologies. Sri International's extensive background in biomedical research, toxicology studies, and interventional agent safety evaluation through prior NIH IDIQ vehicles positions the organization to conduct the necessary scientific testing and evaluation activities. The award reflects the federal government's continued investment in reproductive health research and the development of safe, effective contraceptive options through established research partnerships with premier scientific institutions.
Quick answers
Who was awarded contract 75N94020F00003?
75N94020F00003 was awarded to Sri International by National Institute of Child Health and Human Development (National Institutes of Health) on September 22, 2020.
How much is contract 75N94020F00003 worth?
The government has obligated $696,936 on 75N94020F00003.
Is contract 75N94020F00003 an order under another contract?
Yes. 75N94020F00003 is a delivery order under 75N94020D00003, an indefinite delivery contract.
Was contract 75N94020F00003 competed?
The extent of competition for 75N94020F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award